Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.

NCT06729580 | Completed

• 1 other identifier: CRC245719
• Study Type: interventional
• Target: 118
• Locations: 1 country
• Sites: 1

Brief Summary

Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression. Although a wide range of treatments have been developed for the treatment of MDD, a significant proportion of patients fail to respond. This study examined the effectiveness of a 10-week behavioural activation intervention for individuals with treatment-resistant depression.

Conditions

Treatment Resistant Depression (TRD)

Keywords

treatment resistant depression; catastrophic thinking; perceived injustice; behavioural activation

Outcome Measures

Primary Outcomes (1)

• Depression symptom severity.

  The Patient Health Questionnaire (PHQ9) was used to assess depressive symptom severity. PHQ-9 scores can range from 0 to 27 with higher scores indicating more severe depressive symptoms.

  baseline/immediately after the intervention

Secondary Outcomes (2)

• Catastrophic thinking

  baseline/immediately after the intervention.

• Perceived Injustice

  baseline/immediately after the intervention.

Study Arms (1)

Behavioural Activation for Depression.

EXPERIMENTAL

All participants were enrolled in a 10-week standardized risk-targeted behavioural activation intervention.

Behavioral: Behavioural Activation

Interventions

Behavioural Activation BEHAVIORAL

10-week standardized behavioural activation program.

Behavioural Activation for Depression.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• A diagnosis of Major Depressive Disorder
• The date of diagnosis of MDD preceded referral by at least 12 months
• At least one previous prescription of an antidepressant failed to yield therapeutic response
• Currently taking an antidepressant
• A PHQ9 score in the moderate to severe range of depression at the time of enrolment

You may not qualify if:

• \- Participating in another psychotherapeutic intervention.

Sponsors & Collaborators

• McGill University: lead

Study Sites (1)

McGill University

Montreal, Quebec, H3A 1G1, Canada

Location

MeSH Terms

Conditions

Depressive Disorder, Treatment-Resistant

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• Michael Sullivan, PhD

  McGill University

  PRINCIPAL INVESTIGATOR

• Heather Adams, BSW

  Dalhousie University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: September 30, 2024
• First Posted: December 11, 2024
• Study Start: January 5, 2022
• Primary Completion: October 30, 2023
• Study Completion: October 30, 2023
• Last Updated: December 11, 2024

Record last verified: 2024-09

Locations

CA (1)